Do you want to read an article? Please log in or register.
Use of Vascular Assessments and Novel Biomarkers to Predict Cardiovascular Events in Type 2 Diabetes: The SUMMIT VIP Study
Diabetes - GeneralType 2 Diabetes
COMMENTED
Related content
Diabetes - GeneralType 2 Diabetes
The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial
Diabetes Care.
Dhatariya K, Bain SC, Buse JB, Simpson R, Tarnow L, Kaltoft MS, Stellfeld M, Tornøe K, Pratley RE; LEADER Publication Committee on behalf of the LEADER Trial Investigators
doi: 10.2337/dc18-1094.
COMMENTED
Diabetic Complications
Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register
Diabetes Care.
Read SH, van Diepen M, Colhoun HM, Halbesma N, Lindsay RS, McKnight JA, McAllister DA, Pearson ER, Petrie JR, Philip S, Sattar N, Woodward M, Wild SH; Scottish Diabetes Research Network Epidemiology Group
doi: 10.2337/dc18-0578.
Diabetes - GeneralType 2 DiabetesGlycemic Control
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
Lancet Diabetes Endocrinol.
Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellese AA, Squatrito S, Giorda CB, Sesti G, Mocarelli P, Lucisano G, Sacco M, Signorini S, Cappellini F, Perriello G, Babini AC, Lapolla A, Gregori G, Giordano C, Corsi L, Buzzetti R, Clemente G, Di Cianni G, Iannarelli R, Cordera R, La Macchia O, Zamboni C, Scaranna C, Boemi M, Iovine C, Lauro D, Leotta S, Dall'Aglio E, Cannarsa E, Tonutti L, Pugliese G, Bossi AC, Anichini R, Dotta F, Di Benedetto A, Citro G, Antenucci D, Ricci L, Giorgino F, Santini C, Gnasso A, De Cosmo S, Zavaroni D, Vedovato M, Consoli A, Calabrese M, di Bartolo P, Fornengo P, Riccardi G; Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group; under the mandate of the Italian Diabetes Society
doi: 10.1016/
Type 2 Diabetes
Arterial stiffness as a risk factor for cardiovascular events and all-cause mortality in people with Type 2 diabetes
Diabet Med.
Sharif S, Visseren FLJ, Spiering W, de Jong PA, Bots ML, Westerink J; SMART study group
doi: 10.1111/dme.13954.
Diabetes - GeneralType 2 DiabetesGlycemic Control
Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study
Diabetologia.
Penno G, Solini A, Orsi E, Bonora E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Lamacchia O, Scardapane M, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group
doi: 10.1007/s00125-018-4691-2.
RECOMMENDED
Type 2 Diabetes
Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus
Eur Heart J.
Berkelmans GFN, Gudbjörnsdottir S, Visseren FLJ, Wild SH, Franzen S, Chalmers J, Davis BR, Poulter NR, Spijkerman AM, Woodward M, Pressel SL, Gupta AK, van der Schouw YT, Svensson AM, van der Graaf Y, Read SH, Eliasson B, Dorresteijn JAN
doi: 10.1093/eurheartj/
Diabetes - GeneralType 2 Diabetes
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
Diabetologia.
Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, Zinman B
doi: 10.1007/s00125-018-4644-9.
COMMENTED
Type 2 Diabetes
Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and All-Cause Mortality for Widely Used Antihyperglycemic Dual and Triple Therapies for Type 2 Diabetes Management: A Cohort Study of All Danish Users
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
doi: 10.2337/dc19-2535.
COMMENTED
Diabetes - GeneralType 2 Diabetes
Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study
BMJ
Douros A, Dell'Aniello S, Yu OHY, Filion KB, Azoulay L, Suissa S
doi: 10.1136/bmj.k2693.